Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Millot

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
British Journal of Cancer|January 8, 2004
Infectious diseases in the first year of life, perinatal characteristics and childhood acute leukaemiaN Jourdan-Da Silva, Y Perel, F Méchinaud, et al.
Oncogene|January 29, 2014
SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemiaE Pasmant, B Gilbert-Dussardier, A Petit, et al.
Blood|May 16, 2000
Treatment outcome in infant acute lymphoblastic leukemia. Children Leukemia Cooperative Group--EORTC. European Organization for Research and Treatment of CancerA Ferster, Y Benoit, N Francotte, et al.
British Journal of Cancer|September 20, 2000
Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncologyV Minard, O Hartmann, M C Peyroulet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trialF Millot, S Suciu, N Philippe, et al.
Leukemia|June 9, 2015
IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951E Clappier, N Grardel, M Bakkus, et al.
Pediatric Hematology and Oncology|December 15, 2016
Combined therapy in children and adolescents with classical Hodgkin's lymphoma: A report from the SFCE on MDH-03 national guidelinesE Seror, J Donadieu, H Pacquement, et al.
Leukemia|February 24, 2001
Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative GroupE Vilmer, S Suciu, A Ferster, et al.
Leukemia|October 25, 2017
Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trialsC Piette, S Suciu, E Clappier, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
British Journal of Cancer|January 8, 2004
Infectious diseases in the first year of life, perinatal characteristics and childhood acute leukaemiaN Jourdan-Da Silva, Y Perel, F Méchinaud, et al.
Oncogene|January 29, 2014
SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemiaE Pasmant, B Gilbert-Dussardier, A Petit, et al.
Blood|May 16, 2000
Treatment outcome in infant acute lymphoblastic leukemia. Children Leukemia Cooperative Group--EORTC. European Organization for Research and Treatment of CancerA Ferster, Y Benoit, N Francotte, et al.
British Journal of Cancer|September 20, 2000
Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncologyV Minard, O Hartmann, M C Peyroulet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trialF Millot, S Suciu, N Philippe, et al.
Leukemia|June 9, 2015
IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951E Clappier, N Grardel, M Bakkus, et al.
Pediatric Hematology and Oncology|December 15, 2016
Combined therapy in children and adolescents with classical Hodgkin's lymphoma: A report from the SFCE on MDH-03 national guidelinesE Seror, J Donadieu, H Pacquement, et al.
Leukemia|February 24, 2001
Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative GroupE Vilmer, S Suciu, A Ferster, et al.
Leukemia|October 25, 2017
Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trialsC Piette, S Suciu, E Clappier, et al.
Pageof 7